Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB

Journal of Clinical Investigation

Volumn 107, Issue 3, 2001, Pages 241-246

  Baldwin, A S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR;

CANCER; CANCER IMMUNOLOGY; CARCINOGENESIS; CELLULAR DISTRIBUTION; GENE CONTROL; HUMAN; HUMAN CELL; IMMUNOREGULATION; PRIORITY JOURNAL; REVIEW;

EID: 0035137882     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI11991     Document Type: Review

References (47)

1. NF-κB and Rel proteins: Evolutionarily conserved mediators of immune respones
2. Bridging the gap: Composition, regulation, and physiological function of the IκB kinase complex
3. Phosphorylation of NF-κB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the co-activator CBP/p300
4. Rel/NF-κB/IκB proteins and cancer
5. Aberrant Rel/NF-κB genes and activity in human cancer
6. Bcl-3 rearrangements and t(14;19) in chronic lymphocytic leukemia and other B-cell malignancies: A molecular and cytogenetic study
7. Stuctural alterations of NF-κB transcription factor lyt-10 in lymphoid malignancies
8. Constitutive expression of lymphoma-associated NFκB2/lyr-10 proteins is tumorigenic in murine fibroblasts
9. Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the C-terminal ankyrin domain of NF-κB2
10. Mutations in the IκBα gene in Hodgkin's disease suggest a tumor suppressor role for IκBα
11. Hostile takeovers: Viral appropriation of the NF-kB pathway
12. The Tax oncoprotein of HTLV-I associates with and persistently activates IκB kinases containing IKKα and IKKβ
13. Constitutive activation of NF-κB is essential for transformation of rat fibroblasts by HTVL-I Tax protein
14. The role of Rel/NF-κB proteins in viral oncogenesis and regulation of viral transcription
15. Oncogenic Ha-Ras-induced signaling activates NFκB transcriptional activity which is required for cellular transformation
16. Role of IκB complex in oncogenic Ras- and Raf-mediated transformation of rat liver epithelial cells
17. A requirement for NF-κB activation in Bcr-Abl-mediated transformation
18. Constitutive activation of NF-κB-RelA is required for proliferation and survival of Hodgkin's disease tumor cells
19. Expression of a dominant negative mutant inhibitor of NF-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression and tumor growth in vivo
20. Aberrant NF-κB/Rel expression and pathogenesis of breast cancer
21. Selective activation of NF-κB subunits in human breast cancer: Potential roles for NF-kB2/p52 and for Bcl-3
22. Oncogenic Ras enhances NF-κB transcriptional activity through Raf-dependent and Raf-independent mitogen-activated protein kinase signaling pathways
23. Akt suppresses apoptosis by stimulating the transcriptional activation potential of the RelA/p65 subunit of NF-κB
24. Her-2/Neu blocks TNF-induced apoptosis by stimulating the transactivational potential of the RelA/p65 subunit of NF-κB
25. Control of apoptosis by Rel/NF-κB transcription factors
26. Transcriptional cross-talk between NF-κB and p53
27. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras
28. NF-κB inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells
29. NF-κB is a target of Akt in antiapoptotic PDGF signaling
30. Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus larent membrane protein 1 C-terminal activation regions 1 and 2
31. Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K
32. NF-κB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice
33. Squamous cell carcinoma and increased apoptosis in skin with inhibited Rel/NF-κB signaling
34. Alterations in NF-κB function in transgenic epithelial tissues demonstrate a growth inhibitory role for NF-κB
35. Regulation of Fas-ligand expression during activation-induced cell death of T lymphocytes via NF-κB
36. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-κB and AP-1
37. The NF-κB signaling pathway is nor required for Fas ligand gene induction but mediates protection from activation-induced cell death
38. Role of NF-κB in p53-mediated programmed cell death
39. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer
40. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of IκB kinase
41. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB
42. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB
43. Inducible chemoresistance to CPT-11 in colorectal cancer cells and a xenograft model is overcome by inhibition of NF-κB
44. NF-κB and chemoresistance: Potentiation of cancer chemotherapy via inhibition of NF-κB
45. NF-κB/IκB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells
46. Paclitaxel sensitivity in breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide
47. NF-κB induced loss of MyoD mRNA: Possible role in muscle decay and cachexia